KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Accumulated Depreciation & Amortization (2016 - 2025)

Eli Lilly filings provide 17 years of Accumulated Depreciation & Amortization readings, the most recent being $2.0 billion for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization rose 13.02% to $2.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 billion, a 13.02% increase, with the full-year FY2025 number at $2.0 billion, up 13.02% from a year prior.
  • Accumulated Depreciation & Amortization hit $2.0 billion in Q4 2025 for Eli Lilly, up from $470.0 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $2.0 billion in Q4 2025 to a low of $350.3 million in Q1 2021.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $799.8 million (2022), compared with a mean of $952.0 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 28.03% in 2021 and later crashed 63.33% in 2025.
  • Eli Lilly's Accumulated Depreciation & Amortization stood at $1.5 billion in 2021, then fell by 1.62% to $1.5 billion in 2022, then increased by 0.3% to $1.5 billion in 2023, then rose by 15.72% to $1.8 billion in 2024, then increased by 13.02% to $2.0 billion in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $2.0 billion (Q4 2025), $470.0 million (Q3 2025), and $478.5 million (Q2 2025) per Business Quant data.